Reference · 2026

Glossary

Plain-English definitions for every domain term used on this site. Each entry includes the canonical reference where one exists.

Biology and gene therapy

NKG2D (KLRK1): Natural Killer Group 2D. A C-type lectin activating receptor expressed on NK cells, γδ T cells, and CD8 T cells. Recognizes the stress-induced ligands MICA, MICB, and the ULBP family. The extracellular domain (residues 79-216 in human KLRK1) is the recognition module of the NKG2D-LIF6 chimera. Reference: Bauer et al. 1999, Science 285:727; Lanier 2015, Cancer Immunol Res 3:575.
MICA / MICB: MHC class I chain-related proteins A and B. Stress-induced surface ligands upregulated on transformed, infected, or stressed cells. Largely absent from healthy tissue. The tumor-restricted signal the NKG2D-LIF6 chimera responds to.
LIF6 (elephant): Leukemia Inhibitory Factor 6. A re-functionalized pseudogene unique to elephants and their closest relatives. Activated downstream of TP53 in response to DNA damage; mediates rapid intrinsic apoptosis via mitochondrial outer-membrane permeabilization (BAX/BAK-dependent route). Reference: Vazquez, Sulak, Chigurupati & Lynch 2018, Cell Reports 24(7):1765-1776.
AAV9 (Adeno-associated virus serotype 9): Recombinant viral vector for gene therapy. Broad tissue tropism including muscle, liver, CNS, and many solid-tumor tissues. Cargo capacity ~4.7 kb. Clinically validated (Zolgensma uses AAV9). Used as the delivery vehicle for the NKG2D-LIF6 chimera.
Peto's paradox: Empirical observation that large long-lived organisms do not have cancer rates proportional to their body mass. Elephants are the canonical example: ~100× more cells than humans yet ~4.8% lifetime cancer mortality versus 17-25% in humans. Mechanistically attributed to expanded TP53 copy number (~20 in elephants vs 1 in humans) and re-functionalized pro-apoptotic pseudogenes including LIF6. Reference: Caulin & Maley 2011, Trends Ecol Evol 26:175; Abegglen et al. 2015, JAMA 314:1850.
Chimeric receptor-effector: A single fusion protein combining a recognition module (here: NKG2D ECD) with an effector module (here: elephant LIF6) via a cleavable linker (here: P2A peptide). Architectural alternative to autologous CAR-T cell therapies — the recognition and killing functions are encoded in a single AAV-deliverable construct rather than engineered into patient T cells ex vivo.
P2A self-cleaving peptide: 22-amino-acid peptide (sequence GSGATNFSLLKQAGDVEENPGP) that causes ribosomal skipping during translation, producing two separate proteins from a single open reading frame at near-stoichiometric ratio.
Syngeneic murine tumor model: An in vivo cancer model in which tumor cells are implanted into mice of the same inbred strain as the cell line was derived from — preserving an intact immune system. Standard preclinical context for testing immune-engaging therapies. Common models: CT26 / MC38 (CRC), B16-F10 (melanoma), KPC (pancreatic).
TGI (Tumor Growth Inhibition): Standard preclinical efficacy metric: percent reduction in tumor volume of treated vs control animals. The "~99% TGI ceiling" claim on this site refers to a computational PK-PD model prediction, not measured wet-lab data.

Regulatory and clinical

CBER (Center for Biologics Evaluation and Research): The FDA division responsible for regulating gene therapies, cell therapies, vaccines, blood products, and other biologics. The NKG2D-LIF6 program will engage CBER for pre-IND meeting and IND submission.
RMAT (Regenerative Medicine Advanced Therapy designation): FDA designation under the 21st Century Cures Act for regenerative medicine therapies (including gene therapies) that show preliminary clinical evidence for serious conditions. Confers benefits similar to Breakthrough Therapy designation. Relevant for NKG2D-LIF6 post-Phase 1.
IND (Investigational New Drug application): FDA application required to begin clinical trials in humans. Includes preclinical pharm/tox data, manufacturing (CMC) data, clinical protocol, and investigator brochure. Nightbox target: H2 2026 pre-IND meeting; 2027 IND filing.
Pre-IND meeting: Voluntary meeting with FDA to obtain feedback on planned IND-enabling studies before formal submission. Typical timing: 6-12 months before planned IND submission.
Right-to-Try Act 2018: US federal legislation enabling terminally ill patients to access investigational therapies that have completed Phase 1 trials, outside of formal expanded-access pathways. Relevant for compassionate-use access design.
CMC (Chemistry, Manufacturing, and Controls): The manufacturing-quality portion of an IND/NDA. For gene therapies: AAV vector production, characterization, purity, potency, stability, GMP-grade manufacturing process.

Computational and methodological

In silico: Performed by computational simulation rather than in a living organism (in vivo) or in laboratory cells (in vitro). All current NKG2D-LIF6 efficacy claims are in silico — they are predictions of computational models, not measured experimental outcomes.
AlphaFold: DeepMind's protein structure prediction model. AlphaFold2 (2021) achieved competition-leading accuracy. AlphaFold3 (2024) extended to ligand and complex prediction. Used as the primary structural validation tool for the NKG2D-LIF6 chimera. Reference: Jumper et al. 2021, Nature; Abramson et al. 2024, Nature.
RoseTTAFold all-atom: Independent structure prediction model (Baker lab, Univ of Washington / Institute for Protein Design). Used as a secondary check on chimera linker and effector folding.
PK-PD model (Pharmacokinetic-Pharmacodynamic): Mathematical model coupling drug concentration over time (PK) with drug effect on the biological system (PD). The "~99% TGI ceiling" claim derives from a custom Python PK-PD model parameterized with published AAV9 biodistribution and MICA/B expression data.
Freedom-to-operate (FTO): Patent landscape analysis confirming that a proposed product or method does not infringe existing IP. The NKG2D-LIF6 FTO scan was conducted across USPTO, EPO, WIPO, with cross-checks via Lens.org and Google Patents. Result: clean whitespace identified for the specific chimera.

Federal and contracting

SBIR / STTR (Small Business Innovation Research / Technology Transfer): US federal R&D funding programs reserved for small businesses (≤500 employees). Phases: I (feasibility, ≤$400K, 6-12 months), II (development, ≤$2M, 24 months), III (commercialization). Nightbox target: NIH NCI Phase I for NKG2D-LIF6 wet-lab validation.
NAICS 541714: North American Industry Classification System code for "Research and Development in Biotechnology (except Nanobiotechnology)" — Nightbox's primary NAICS for federal contracting.
UEI (Unique Entity Identifier): Federal contractor identifier issued through SAM.gov, replacing DUNS as of April 2022. Required for all federal contracting and grant submissions.
CAGE code: Commercial and Government Entity code, issued by DLA. Auto-issued with SAM.gov entity registration. Required for DoD contracting.
ARPA-H: Advanced Research Projects Agency for Health. DARPA-style biomedical agency under HHS, established 2022. Funds high-risk high-reward health research. Nightbox target: Cancer Moonshot 2.0 portfolio.
BARDA: Biomedical Advanced Research and Development Authority, under HHS ASPR. Funds advanced development of medical countermeasures against CBRN threats and pandemic agents. Nightbox target: DRIVe accelerator + EZ-BAA channel.

Suggested addition? research@nightboxllc.com — pull requests welcome at github.com/nightbox-llc/nightbox-website.